
|Articles|July 31, 2007
Survey: What Will You Do About Rosiglitazone (Avandia)?
Take this MedPage Today survey.
Advertisement
On Monday, a special FDA advisory panel recommended that rosiglitazone (Avandia) stay on the market, despite an acknowledged increase in ischemic heart risks for type 2 diabetes patients. A meta-analysis published this spring linked the drug to a 43% increase in risk of myocardial infarction.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management
2
Zasocitinib Demonstrates Superiority vs Placebo and Apremilast in Phase 3 Plaque Psoriasis Trials
3
FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH
4
Hidradenitis Suppurativa: A Comprehensive Care Plan for Primary Care
5


















































































































































































































































































